IN8bio Doubles Glioblastoma Survival Rates, Secures $40M Financing
Event summary
- IN8bio's DeltEx γδ T cell therapy nearly doubled median progression-free survival in glioblastoma patients to 13.0 months vs. 6.6 months in standard-of-care control.
- Closed $20.1M tranche of a private placement with potential for up to $40.2M, extending cash runway into H1 2027.
- Promoted Kate Rochlin, Ph.D., to President and Chief Operating Officer in February 2026.
- Reduced full-year net loss by 36% YoY while doubling year-end cash position.
The big picture
IN8bio's durable survival improvements in glioblastoma position it as a potential leader in γδ T cell therapies, while the $40M financing strengthens its balance sheet for pipeline advancement. The company's ability to secure repeat dosing approvals and expand into autoimmune indications will be critical in sustaining its competitive edge.
What we're watching
- Regulatory Pathway
- Whether FDA guidance in H2 2026 will accelerate IN8bio's glioblastoma program approval.
- Pipeline Execution
- The pace at which INB-619 γδ T cell engager advances through IND-enabling studies.
- Financial Discipline
- How efficiently IN8bio deploys its $40.2M financing across multiple high-value programs.
Related topics